![]() |
Name |
Ethyl 2-octynoate
|
Molecular Formula | C10H16O2 | |
IUPAC Name* |
ethyl oct-2-ynoate
|
|
SMILES |
CCCCCC#CC(=O)OCC
|
|
InChI |
InChI=1S/C10H16O2/c1-3-5-6-7-8-9-10(11)12-4-2/h3-7H2,1-2H3
|
|
InChIKey |
QPMDWYXUSMRVKT-UHFFFAOYSA-N
|
|
Synonyms |
Ethyl 2-octynoate; Ethyl oct-2-ynoate; 10519-20-7; 2-Octynoic acid, ethyl ester; 2-Octynoic Acid Ethyl Ester; Ethyl 2-octynate; Ethyl heptynecarbonate; XTH780U0N3; NSC-74485; Ethyl heptine carbonate; EINECS 234-058-5; ethyl n-oct-2-ynoate; AI3-35774; Ethyl heptyne carboxylate; ETHYL PENTYLPROPIOLATE; UNII-XTH780U0N3; SCHEMBL1089589; DTXSID9065104; QPMDWYXUSMRVKT-UHFFFAOYSA-; NSC74485; ZINC1621003; ETHYL 2-OCTYNOATE, 98%,; MFCD00015286; AKOS006229393; AS-76426; DB-040594; CS-0297444; FT-0625977; O0253; EN300-786984; A801162; (E)-ethyl 2-(4-(cyclopropylthio)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate
|
|
CAS | 10519-20-7 | |
PubChem CID | 66338 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 168.23 | ALogp: | 3.5 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 12 | QED Weighted: | 0.279 |
Caco-2 Permeability: | -4.085 | MDCK Permeability: | 0.00003150 |
Pgp-inhibitor: | 0.016 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.929 |
30% Bioavailability (F30%): | 0.985 |
Blood-Brain-Barrier Penetration (BBB): | 0.514 | Plasma Protein Binding (PPB): | 95.72% |
Volume Distribution (VD): | 1.62 | Fu: | 2.01% |
CYP1A2-inhibitor: | 0.976 | CYP1A2-substrate: | 0.651 |
CYP2C19-inhibitor: | 0.911 | CYP2C19-substrate: | 0.543 |
CYP2C9-inhibitor: | 0.849 | CYP2C9-substrate: | 0.932 |
CYP2D6-inhibitor: | 0.045 | CYP2D6-substrate: | 0.289 |
CYP3A4-inhibitor: | 0.37 | CYP3A4-substrate: | 0.121 |
Clearance (CL): | 9.069 | Half-life (T1/2): | 0.276 |
hERG Blockers: | 0.031 | Human Hepatotoxicity (H-HT): | 0.015 |
Drug-inuced Liver Injury (DILI): | 0.548 | AMES Toxicity: | 0.103 |
Rat Oral Acute Toxicity: | 0.06 | Maximum Recommended Daily Dose: | 0.016 |
Skin Sensitization: | 0.949 | Carcinogencity: | 0.531 |
Eye Corrosion: | 0.988 | Eye Irritation: | 0.986 |
Respiratory Toxicity: | 0.547 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001190 | ![]() |
0.500 | D01QLH | ![]() |
0.310 | ||
ENC000371 | ![]() |
0.462 | D0AY9Q | ![]() |
0.293 | ||
ENC001025 | ![]() |
0.425 | D0Y3KG | ![]() |
0.255 | ||
ENC000248 | ![]() |
0.412 | D06ORU | ![]() |
0.234 | ||
ENC000776 | ![]() |
0.410 | D08HQK | ![]() |
0.229 | ||
ENC000655 | ![]() |
0.404 | D0H2SY | ![]() |
0.221 | ||
ENC000245 | ![]() |
0.395 | D0Y4AW | ![]() |
0.220 | ||
ENC000738 | ![]() |
0.395 | D0G2KD | ![]() |
0.218 | ||
ENC000254 | ![]() |
0.390 | D0FD0H | ![]() |
0.213 | ||
ENC000235 | ![]() |
0.390 | D05ATI | ![]() |
0.212 |